迈得医疗工业设备股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688310 证券简称：迈得医疗 公告编号：2026-009 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 2 月 9 日 （二） 股东会召开的地点：浙江省玉环市沙门镇滨港工业城迈得医疗工业设备 股份有限公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 40 | | --- | --- | | 普通股股东人数 | 40 | | 2、出席会议的股东所持有的表决权数量 | 2,028,668 | | 普通股股东所持有表决权数量 | 2,028,668 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 3.8075 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 3.8075 | 注：截 ...

Core Viewpoint - The stock of Maide Medical (688310) has shown a positive performance with a closing price of 17.39 yuan, reflecting a 3.82% increase as of February 6, 2026, with notable trading activity and capital flow dynamics [1] Group 1: Stock Performance - As of February 6, 2026, Maide Medical's stock closed at 17.39 yuan, up by 3.82% with a turnover rate of 3.92% and a trading volume of 65,100 hands, resulting in a transaction amount of 113 million yuan [1] - The net outflow of main funds was 1.0271 million yuan, accounting for 0.91% of the total transaction amount, while retail investors experienced a net outflow of 4.4725 million yuan, representing 3.95% of the total transaction amount [1] Group 2: Financing and Margin Trading - On February 6, 2026, the financing data indicated a financing buy of 11.3982 million yuan and a financing repayment of 12.9902 million yuan, resulting in a net repayment of 1.5919 million yuan [2] - The margin trading balance stood at 62.2655 million yuan, with no shares sold or repaid in the short selling segment [2] Group 3: Financial Performance - For the first three quarters of 2025, Maide Medical reported a main revenue of 225 million yuan, a year-on-year increase of 2.31%, and a net profit attributable to shareholders of 8.8367 million yuan, up by 15.82% year-on-year [3] - In Q3 2025, the company achieved a single-quarter main revenue of 83.643 million yuan, reflecting a significant year-on-year increase of 54.38%, and a net profit of 2.7916 million yuan, which is a remarkable increase of 224.07% year-on-year [3] - The company reported a debt ratio of 29.86%, an investment income of 167,600 yuan, financial expenses of -523,600 yuan, and a gross profit margin of 40.19% [3] Group 4: Business Overview - Maide Medical specializes in the research, production, sales, and service of medical consumables and intelligent equipment, effectively integrating technology in medical device processes, automation, and software to create unique product and service advantages [3]

Group 1 - The core viewpoint of the news is that Maide Medical has shown a stable performance in terms of financing and stockholder changes, indicating a solid position in the medical equipment industry [1][2]. Group 2 - As of February 2, Maide Medical's stock price increased by 0.61%, with a trading volume of 95.09 million yuan. The financing buy-in amount was 9.29 million yuan, while the financing repayment was 8.92 million yuan, resulting in a net financing buy of 0.38 million yuan [1]. - The total financing and securities balance for Maide Medical reached 69.66 million yuan, accounting for 2.56% of its circulating market value, which is above the 70th percentile level over the past year [1]. - The company has not engaged in any short selling activities on February 2, with a short selling balance of 0.00 yuan, indicating a high level of confidence among investors [1]. Group 3 - As of September 30, the number of shareholders for Maide Medical increased to 4,528, a rise of 19.00%, while the average circulating shares per person decreased by 15.97% to 36,709 shares [2]. - For the period from January to September 2025, Maide Medical reported a revenue of 225 million yuan, reflecting a year-on-year growth of 2.31%, and a net profit attributable to shareholders of 8.84 million yuan, which is a 15.82% increase compared to the previous year [2]. - The company has distributed a total of 202 million yuan in dividends since its A-share listing, with 99.30 million yuan distributed over the last three years [2]. Group 4 - Among the top ten circulating shareholders as of September 30, 2025, Huaxia Industry Prosperity Mixed Fund (003567) is the fourth largest with 2.60 million shares, having decreased its holdings by 1.07 million shares. New entrants include the交银稳健配置混合 (519690) and 交银科技创新灵活配置混合A (519767) [2].

Group 1 - The company has approved a share repurchase plan using funds from its initial public offering or its own funds, with a total repurchase amount between RMB 20 million and RMB 40 million, and a maximum repurchase price of RMB 24 per share [1] - As of January 2026, the company has repurchased a total of 1,297,052 shares, representing 0.7803% of the total share capital of 166,219,690 shares, with a total expenditure of RMB 20,660,204.79 [2][3] - The repurchase activities are in compliance with relevant laws and regulations, and the company will continue to make repurchase decisions based on market conditions within the specified timeframe [4]

Group 1 - The company Maide Medical announced on February 2 that it has repurchased approximately 1.3 million shares through centralized bidding, accounting for 0.7803% of its total share capital of approximately 166 million shares [1] - The highest repurchase price was 16.2 yuan per share, while the lowest was 15.69 yuan per share, with a total expenditure of approximately 20.66 million yuan [1] Group 2 - The automotive sales giant Baolide, known for selling luxury cars such as Rolls-Royce and Porsche, is now undergoing bankruptcy liquidation, with its headquarters in Hangzhou reportedly abandoned and its subsidiary in Yiwu sealed [1]

迈得医疗工业设备股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/12/13 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 12 | 12 | 月 | 30 | 日~2026 | 年 | 月 | 29 | 日 | | 预计回购金额 | 2,000万元~4,000万元 | | | | | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | | | | | | | □用于转换公司可转债 | | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | | 累计已回购股数 | 1,297,052股 | | | | | | | | | | 累计已回购股数占总股本比例 | 0.7803% | | | | | | ...

Summary of Key Points Core Viewpoint - The company, Maide Medical (688310.SH), has conducted a share buyback, acquiring a total of 1,297,052 shares, which represents 0.7803% of its total share capital [1] Group 1: Share Buyback Details - The share buyback was executed through centralized bidding transactions [1] - The highest price paid for the shares was 16.20 CNY per share, while the lowest price was 15.69 CNY per share [1] - The total amount spent on the buyback was 20,660,204.79 CNY, excluding transaction fees such as stamp duty and commissions [1]

格隆汇2月2日丨迈得医疗(688310.SH)公布，截至2026年1月31日，本次公司通过集中竞价交易方式已累 计回购公司股份1,297,052股，占公司总股本的比例为0.7803%，回购成交的最高价为16.20元/股，最低 价为15.69元/股，支付的资金总额为人民币20,660,204.79元（不含印花税、交易佣金等交易费用）。 ...

截至2026年1月30日收盘，迈得医疗(688310)报收于16.3元，上涨1.62%，换手率2.2%，成交量3.66万 手，成交额5921.43万元。 公司公告汇总 迈得医疗工业设备股份有限公司拟向控股子公司浙江迈得顺隐形眼镜有限公司提供总额不超过人民币1 亿元的财务资助，资助期限为自股东会审议通过之日起3年内，借款利率参照一年期LPR，利息按实际 借款占用天数计算。迈得顺可循环使用额度。公司实际控制人林军华、持股5%以上股东陈万顺为本次 资助提供连带责任保证。本次资助事项构成关联交易，不构成重大资产重组。董事会已提请股东会授权 管理层办理相关协议签署及款项支付等事宜。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月30日主力资金净流出114.8万元，占总成交额1.94%。 来自公司公告汇总：迈得医疗拟向控股子公司浙江迈得顺提供不超过1亿元财务资助，借款利率参 照一年期LPR。 当日关注点 交易信息汇总资金流向 1月30日主力资金净流出114.8万元，占总成交额1.94%；游资资金净流出279.94万元，占 ...

公司公告汇总 迈得医疗拟向控股子公司浙江迈得顺隐形眼镜有限公司提供总额不超过1亿元的财务资助，期限自股东 会审议通过之日起3年内，借款利率参照一年期LPR，利息按实际占用天数计算，额度可循环使用。公 司实控人林军华及持股5%以上股东陈万顺为本次资助提供连带责任保证。该事项构成关联交易，不构 成重大资产重组。董事会已提请股东会授权管理层办理相关协议签署及付款事宜。 截至2026年1月30日收盘，迈得医疗（688310）报收于16.3元，较上周的16.52元下跌1.33%。本周，迈 得医疗1月27日盘中最高价报18.0元。1月30日盘中最低价报15.87元。迈得医疗当前最新总市值27.09亿 元，在自动化设备板块市值排名73/78，在两市A股市值排名4838/5184。 本周关注点 业绩披露要点 迈得医疗发布业绩预告，预计2025年全年营业收入44,749.77万元左右，同比增长62.81%；归属于母公 司所有者的净利润为6,652.13万元左右，实现扭亏为盈；扣除非经常性损益后的净利润为5,463.95万元左 右。业绩增长主要得益于药械组合类智能装备收入显著提升。本期业绩预告未经注册会计师审计。 以上内容为证券 ...